Biotech | January 21, 2022
Palleon announces IND clearance for first-in-class cancer immunotherapy
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
However, these won’t be available at the nearest chemist store soon
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
First launches expected in H1 2022
Ram’s appointment follows the launch of the CDI India division in October 2021.
Subscribe To Our Newsletter & Stay Updated
